Your browser doesn't support javascript.
Pharmacometric and Electrocardiographic Evaluation of Chloroquine and Azithromycin in Healthy Volunteers.
Chotsiri, Palang; Tarning, Joel; Hoglund, Richard M; Watson, James A; White, Nicholas J.
  • Chotsiri P; Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
  • Tarning J; Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
  • Hoglund RM; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, Oxford University, Oxford, UK.
  • Watson JA; Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
  • White NJ; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, Oxford University, Oxford, UK.
Clin Pharmacol Ther ; 112(4): 824-835, 2022 Oct.
Artículo en Inglés | MEDLINE | ID: covidwho-1858580
ABSTRACT
Chloroquine and azithromycin were developed in combination for the preventive treatment of malaria in pregnancy, and more recently were proposed as coronavirus disease 2019 (COVID-19) treatment options. Billions of doses of chloroquine have been administered worldwide over the past 70 years but concerns regarding cardiotoxicity, notably the risk of torsades de pointes (TdP), remain. This investigation aimed to characterize the pharmacokinetics and electrocardiographic effects of chloroquine and azithromycin observed in a large previously conducted healthy volunteer study. Healthy adult volunteers (n = 119) were randomized into 5 arms placebo, chloroquine alone (600 mg base), or chloroquine with either 500 mg, 1,000 mg, or 1,500 mg of azithromycin all given daily for 3 days. Chloroquine and azithromycin levels, measured using liquid-chromatography tandem mass spectrometry, and electrocardiograph intervals were recorded at frequent intervals. Time-matched changes in the PR, QRS, and heart rate-corrected JT, and QT intervals were calculated and the relationship with plasma concentrations was evaluated using linear and nonlinear mixed-effects modeling. Chloroquine and azithromycin pharmacokinetics were described satisfactorily by two- and three-compartment distribution models, respectively. No drug-drug interaction between chloroquine and azithromycin was observed. Chloroquine resulted in concentration-dependent prolongation of the PR, QRS, JTc and QTc intervals with a minimal additional effect of azithromycin. QRS widening contributed ~ 28% of the observed QT prolongation. Chloroquine causes significant concentration-dependent delays in both ventricular depolarization and repolarization. Co-administration of azithromycin did not significantly increase these effects. The arrhythmogenic risk of TdP associated with chloroquine may have been substantially overestimated in studies which did not separate electrocardiograph QRS and JT prolongation.
Asunto(s)

Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: Neumonía Viral / Síndrome de QT Prolongado / Torsades de Pointes / Infecciones por Coronavirus / Tratamiento Farmacológico de COVID-19 / Antimaláricos Tipo de estudio: Estudio experimental / Estudio pronóstico / Ensayo controlado aleatorizado Límite: Adulto / Humanos Idioma: Inglés Revista: Clin Pharmacol Ther Año: 2022 Tipo del documento: Artículo País de afiliación: Cpt.2665

Similares

MEDLINE

...
LILACS

LIS


Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: Neumonía Viral / Síndrome de QT Prolongado / Torsades de Pointes / Infecciones por Coronavirus / Tratamiento Farmacológico de COVID-19 / Antimaláricos Tipo de estudio: Estudio experimental / Estudio pronóstico / Ensayo controlado aleatorizado Límite: Adulto / Humanos Idioma: Inglés Revista: Clin Pharmacol Ther Año: 2022 Tipo del documento: Artículo País de afiliación: Cpt.2665